Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate
The production agreement is part of AstraZeneca’s recently announced in-licensed programme with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit during the COVID-19 pandemic.
Find Out More.png "Cobra Biologics Reveals New Brand Identity")
Cobra Biologics Reveals New Brand Identity
In January 2020, following the completion of a successful acquisition process, Cobra Biologics became part of the Cognate Bioservices family. In the months since, the teams have been working closely to align operations, evolve joint service offerings and to create a distinctive, new brand identity.
Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade
The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.
Find Out More
Get In Touch
Speak to a member of our expert team and arrange to take a tour of our GMP facilities in the UK and Sweden.
